Rankings
▼
Calendar
ALT FY 2020 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena
ALT
Altimmune, Inc.
$331M
FY 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$8M
+41.1% YoY
Gross Profit
-$25M
-309.4% margin
Operating Income
-$55M
-669.5% margin
Net Income
-$49M
-599.2% margin
EPS (Diluted)
$-1.91
Cash Flow
Operating Cash Flow
-$34M
Free Cash Flow
-$35M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$245M
Total Liabilities
$19M
Stockholders' Equity
$226M
Cash & Equivalents
$116M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$8M
$6M
+41.1%
Gross Profit
-$25M
$6M
-536.5%
Operating Income
-$55M
-$21M
-155.3%
Net Income
-$49M
-$21M
-139.0%
← Q4 2019
All Quarters
Q1 2020 →